サインイン 無料でサインアップします。

Génomic Vision SAの浮動株式数

Génomic Vision SAの浮動株式数は何ですか。

Génomic Vision SAの浮動株式数は51.222M 51.58%です。

浮動株式数の定義は何ですか。

浮動株式数は、ロックインされた株式とは対照的に、公的投資家の手にある企業の株式の一部です。

Shares float represents the portion of shares of a corporation that are in the hands of public investors as opposed to locked-in stock held by promoters, company officers, controlling-interest investors, or government. This number is sometimes seen as a better way of calculating market capitalization because it provides a more accurate reflection of what public investors consider the company to be worth. In this context, the float may refer to all the shares outstanding that can be publicly traded

The float is calculated by subtracting the locked-in shares from outstanding shares. Stocks with smaller floats tend to be more volatile than those with larger floats. In general, the large holdings of founding shareholders, corporate cross-holdings, and government holdings in partially privatized companies are excluded when calculating the size of a public float.

EURONEXTのセクタHealth Careにおける浮動株式数の企業と比べるGénomic Vision SA

Génomic Vision SAは何をしますか。

Genomic Vision Société Anonyme, a molecular diagnostics and technology company, engages in the development of single DNA detection tools for research and in vitro diagnostics in France. The company offers FiberVision, a molecular combing platform that helps in DNA analysis workflow; FiberComb, a molecular combing system, which stretches single DNA molecules onto a vinyl silane glass surface; FiberVision, a scanner that acquires high resolution images of the whole surface of the coverslip with a hands-off workflow; FiberStudio, a software, which detects hybridization signals and analyzes data to generate results and reporting; FiberPrep, a DNA extraction kit that delivers purified DNA solutions for molecular combing; and accessories, such as custom treated glass carriers and disposable DNA reservoirs for use with the MCS, as well as sample cartridges for scanners. It also provides FiberProbes for BRCA that is a set of Genomic Morse Codes for the detection of mutations occurring in hereditary breast and ovarian cancer; and hereditary nonpolyposis colorectal cancer Genomic Morse Code sets, which allows the identification and characterization of various structural variations, including anomalies occurring in flanking regions of the MMR genes. In addition, the company offers combing services that allow customers to validate the planned gene editing events; detect incorrect events larger than 1kb, including incorrect deletions, insertions, or inversions; and quantify off-target/on-target ratios. It has a strategic alliance with Quest Diagnostics; and development agreement with La Timone Hospital; research and development agreement with the Institut Pasteur. Genomic Vision Société Anonyme was founded in 2004 and is headquartered in Bagneux, France.

Génomic Vision SAと類似の浮動株式数